Literature DB >> 20574756

Combined oral anticoagulant and antiplatelet treatment: need for an evidence-based approach.

Marco Moia1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20574756     DOI： 10.1007/s11739-010-0418-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  8 in total

1.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Marco Moia; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

Review 2.  Combined oral anticoagulants and antiplatelets: benefits and risks.

Authors:  Maria Cristina Vedovati; Cecilia Becattini; Giancarlo Agnelli
Journal:  Intern Emerg Med       Date:  2010-02-11       Impact factor: 3.397

3.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Authors:  Gregory W Albers; Hans-Christoph Diener; Lars Frison; Margaretha Grind; Mark Nevinson; Stephen Partridge; Jonathan L Halperin; Jay Horrow; S Bertil Olsson; Palle Petersen; Alec Vahanian
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

4.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

5.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

Authors:  Michael D Ezekowitz; Paul A Reilly; Gerhard Nehmiz; Timothy A Simmers; Rangadham Nagarakanti; Kambiz Parcham-Azad; K Erik Pedersen; Dominick A Lionetti; Joachim Stangier; Lars Wallentin
Journal:  Am J Cardiol       Date:  2007-08-17       Impact factor: 2.778

6.  Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.

Authors:  M G Bousser; J Bouthier; H R Büller; A T Cohen; H Crijns; B L Davidson; J Halperin; G Hankey; S Levy; V Pengo; P Prandoni; M H Prins; W Tomkowski; C Torp-Pedersen; C Thorp-Pedersen; D G Wyse
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.